GNRHR and ovarian carcinoma: In order to inhibit eIF4E in ovarian cancers, Ko et al. [125] designed 4EBP-based peptide fused to an analog of gonadotropin-releasing hormone (GnRH) to specifically target ovarian and other endocrine cancer cells, that are widely overexpressing the GnRH receptor.